Workshops promise to get boards up to speed on conflicts of interest

27 July 2017

NHS England has published updated guidance for CCGs on managing conflicts of interest. This is to ensure the CCG guidance is fully aligned with the recently published cross system conflicts of interest guidance.

NHS England requires all governing body members to undergo online training in respect of conflicts of interest. However we believe there are no hand-books, rules or algorithms that can be universally followed to give the “right” answers.

There have been several cases in the news recently when decisions made by public bodies have been held to account by local people, politicians and the press. Managing conflicts, to ensure that organisations make the best possible decisions, is a discipline founded in judgements and balance of risk.

So while online training is great as a cost-effective introduction and for awareness raising, the greatest value comes from discussion and talking through scenarios with colleagues. There are no substitutes for face to face workshops.

In this workshop, the board members work together to discuss potential issues. They develop, for themselves, a common language and range of perspectives with which to identify and resolve real issues locally when they arise.

The standard workshop takes three hours and is approximately two thirds discussion based. Boards that take part are able to identify potential concerns, have an understanding of how to collectively approach and issue and have greater confidence in their local arrangements when making and taking decisions. The workshop, which is delivered on site at the organisation’s offices, can be adapted to address live local scenarios for a small additional cost.

To make the workshop even more cost-effective, it can be shared by two or more similar organisations up to a total of 45 participants.

To find out more or to book a session for your CCG, email enquiries@pcc-cic.org.uk with the subject line “COI training”.

Our Services

Latest News

New code of conduct for AI systems

20 February 2019

The Department of Health and Social Care has issued a code of conduct for artificial intelligence (AI) and other data-driven technologies will ensure that only the best and safest systems are used by the NHS.

The code encourages technology companies to meet a gold-standard set of principles to protect patient data to the highest standards. It has been drawn up with the help of industry, academics and patient groups.

The aim is to make it easier for suppliers to develop technologies that tackle some of the biggest issues in healthcare, such as dementia, obesity and cancer. It will also help health and care providers choose safe, effective and secure technology to improve the services they provide.

Read More

More on GMS contract changes 2019/20

20 February 2019

NHS England has written to directors of primary care and senior CCG managers with further details of changes to the GMS contract for 2019/20. It includes notification of the one-off payment for indemnity inflation, changes to the value of QOF, global sum and out-of-hours payments, and the £1.761 per weighted patient for signing up to the forthcoming network contract directed enhanced service (DES).

Read More

Tobacco control assessment tools

19 February 2019

Self-assessment tools from Public Health England help local public health bodies to scrutinise their tobacco control work.

Read More

EU advice notice on falsified medicines directive

19 February 2019

The Safety Features Delegated Regulation, part of the EU Falsified Medicines Directive (FMD), will apply in the UK from 9 February 2019. Healthcare institutions are required to verify and decommission medicines supplied or administered directly to patients. All GP practices “personally administer” some medications and the decommissioning of these elements are covered by the GPIT operating model arrangements and centrally funded. According to the Medicines and Healthcare products Regulatory Agency (MHRA) FMD requirements would need to removed from law in the event of a no deal EU exit as we would no longer have access to the EU system. FMD preparations need to continue “with appropriate caution” given the possibility of a no deal scenario, the MHRA says.

Read More

NICE draft guidance recommends pertuzumab for early treatment of breast cancer

19 February 2019

NICE has published guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.

Read More